FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.
News|Articles|July 15, 2024
Understanding the Significant Role of Secondary Symptoms of Parkinson Disease
Author(s)Marco Meglio
Fact checked by: Matt Hoffman
Secondary symptoms of PD can be as debilitating as the primary motor symptoms, often leading to increased disability, reduced independence, and a higher burden on caregivers.
Advertisement
Advertisement
Parkinson disease (PD), a progressive neurodegenerative disorder involving multiple neurotransmitter pathways in the brain and autonomic nervous system, has been typically characterized by motor symptoms including tremor, bradykinesia, rigidity, and postural reflex disturbance. Although these dopaminergic motor symptoms are a major part of the clinical management of the disease, a growing number of patients have expressed that the nonmotor, secondary symptoms affect their quality of life even more.
Related to this article
A recently published study showed that Qihuang needle acupuncture significantly improved motor function, nonmotor symptoms, and quality of life in patients with PD when added to standard medication.
The phase 3 HARMONIA trial will evaluate whether a muscle- and CNS-targeted antisense conjugate improves function across multiple systems in patients with myotonic dystrophy type 1.
In a discrete choice experiment, somnolence risk and short-term efficacy were the top factors driving vesicular monoamine transporter 2 inhibitor selection for tardive dyskinesia in patients aged 55 years and older.
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
In recognition of World Alzheimer's Day, NeurologyLive reviews Alzheimer disease developments from 2026, spanning blood-based biomarkers, emerging treatments, prevention research, disease risk factors, and safety considerations surrounding anti-amyloid therapies.
Advertisement
Advertisement